BioSpace News Archive

Centene Corporation announced its financial results for the second quarter ended June 30, 2021, reporting diluted loss per share of $ and adjusted diluted earnings per share of $1.25.

Centogene N.V., a commercial-stage company focused on generating data-driven insights to diagnose, understand, and treat rare diseases, announced the appointment of Dr. Patrice P. Denèfle as Chief Scientific Officer.

Aravive, Inc., a clinical-stage oncology company developing innovative therapeutics to treat life-threatening diseases, announced that Gail McIntyre, Ph.D., DABT, Chief Executive Officer of Aravive, and Reshma Rangwala, M.D., Ph.D., Chief Medical Officer of Aravive, will participate in a virtual fireside chat at the 2021 BTIG Biotechnology Conference on August 9, 2021, at 9:30 AM ET.

Matinas BioPharma Holdings, Inc. announced that the Company will host a conference call and live audio webcast on Tuesday, August 10, 2021 at 8:00 a.m. ET to discuss operational and financial results for the second quarter ended June 30, 2021.

Bio-Techne Corporation announced the expansion of the Advanced Cell Diagnostics, a Bio-Techne brand, RNAscope in situ hybridization technology portfolio with the release of new RNAscope HiPlex V2 assay for formalin-fixed paraffin-embedded and fixed and fresh frozen samples for up to 12 targets.

Regeneron Pharmaceuticals, Inc. and AstraZeneca announced that the companies have entered into a collaboration to research, develop and commercialize small molecule compounds directed against the GPR75 target with the potential to treat obesity and related co-morbidities.

Cogent Biosciences, Inc., a biotechnology company focused on developing precision therapies for genetically defined diseases, announced that Andrew Robbins, Chief Executive Officer and President, will present at the Wedbush PacGrow Healthcare Conference on Tuesday, August 10th, from 10:55 -11:25am ET.

Organon, a global women’s health company and ObsEva, a biopharmaceutical company dedicated to improving women’s reproductive health, announced that the companies have entered into an agreement whereby Organon will license the global development, manufacturing and commercial rights to ebopiprant.

Artios Pharma Limited, a leading DNA Damage Response company exploiting a broad DDR-based platform and small molecule drug discovery capabilities to develop a diverse pipeline of product candidates for the treatment of cancer, announced the completion of a US$153 million Series C financing to fund further development of its promising clinical-stage pipeline.

The growing prevalence of lifestyle disease and rising number of elderly population are some of the key factors stimulating growth of the global wearable skin patch market in the coming years.